FREE Webinar

Tuesday, July 28, 2020
2:30 - 4:00 PM, Eastern Standard Time

Register Now

SARS-CoV-2 is characterized by its rapid spread and significant human-to-human transmission. With no approved vaccines or treatments yet available, researchers are exploring various medical interventions, including neutralizing monoclonal antibodies (mAbs), to control the global COVID-19 pandemic. The SARS-CoV-2 spike (S) glycoprotein, which promotes entry into host cells, is the main target of neutralizing antibodies. In this multisponsored webinar by The Scientist, a panel of researchers will discuss potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.

Topics to be covered

  • Human monoclonal antibodies for SARS-CoV-2
  • SARS-CoV-2 neutralizing antibodies for global access

Register Now

Meet the Speakers:

James E. Crowe, Jr., MD
Director, Vanderbilt Vaccine Center
Professor, Pediatrics and Pathology, Microbiology and Immunology
Ann Scott Carrell Chair

Devin Sok, PhD
Senior Director, Antibody Discovery and Development

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?